Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30

We previously found that a low dose of sorafenib had a prometastatic effect on hepatocellular carcinoma (HCC), which was caused by downregulation of TIP30 expression. More recently, metformin has been shown to have potential as a preventive and therapeutic agent for different cancers, including HCC....

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Zhigui, Cao, Manqing, You, Abin, Gao, Junrong, Zhou, Hongyuan, Li, Huikai, Cui, Yunlong, Fang, Feng, Zhang, Wei, Song, Tianqiang, Li, Qiang, Zhu, Xiaolin, Sun, Huichuan, Zhang, Ti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832852/
https://www.ncbi.nlm.nih.gov/pubmed/26752068
http://dx.doi.org/10.1111/cas.12885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832852/
https://www.ncbi.nlm.nih.gov/pubmed/26752068
http://dx.doi.org/10.1111/cas.12885

Ejemplares similares